Carvedilol for Prevention of Paroxysmal Atrial Fibrillation
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder and is associated
with significant symptoms and health problems including an increased risk of stroke and
death. Current drug therapies are often ineffective and associated with significant side
effects. Abnormalities of calcium regulation in cells may lead to triggers for AF. Emerging
data suggest that abnormal intracellular calcium regulation mediated through the ryanodine
receptor in heart cells may contribute to AF. Recently the investigators have shown that the
β-blocker carvedilol which is most commonly used to treat patients with heart failure,
modifies calcium regulation mediated through the ryanodine receptor. At present this drug is
not frequently used to treat AF. Therefore the investigators will conduct a randomized trial
comparing carvedilol to metoprolol for prevention of paroxysmal AF. This may result in
improved health and quality of life for people who suffer AF.
Phase:
N/A
Details
Lead Sponsor:
University of Calgary
Collaborators:
Heart and Stroke Foundation of Canada Libin Cardiovascular Institute of Alberta